{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:28:11Z","timestamp":1763458091118,"version":"build-2065373602"},"reference-count":24,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Tumor mutational burden (TMB) refers to the number of somatic mutations in a tumor per megabase and is a biomarker for response to immune checkpoint inhibitor therapy. Immune checkpoint inhibitors are currently approved for tumors with TMB greater than or equal to 10 mutations\/megabase. Many laboratories are currently reporting TMB values based upon targeted resequencing panels with limited genomic coverage. Due to sampling variation, this leads to significant uncertainty in the assay\u2019s TMB result, particularly at relatively low TMB levels near the 10 mutation per megabase therapeutic threshold. In order to allow clinicians and laboratorians to explore this uncertainty, we built a novel web application that allows a user to view the potential error of a TMB result given the sequencing panel size. This application also allows the user to explore the effect of incorporating knowledge of a specific tumor type\u2019s typical TMB distribution on the error profile of the TMB result.<\/jats:p>","DOI":"10.3390\/genes13030432","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T20:46:17Z","timestamp":1645994777000},"page":"432","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Visualization of the Effect of Assay Size on the Error Profile of Tumor Mutational Burden Measurement"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-680X","authenticated-orcid":false,"given":"Nathanael G.","family":"Bailey","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Pittsburgh and UPMC, Pittsburgh, PA 15213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.annonc.2020.07.001","article-title":"The FDA approval of pembrolizumab for patients with TMB >10 mut\/Mb: Was it a wise decision? No","volume":"31","author":"Prasad","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","article-title":"Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase","volume":"7","author":"Valero","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc2031965","article-title":"The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors","volume":"384","author":"Rousseau","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13073-016-0333-9","article-title":"The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine","volume":"8","author":"Garofalo","year":"2016","journal-title":"Genome Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/ijc.32002","article-title":"Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: In silico and real-life analysis of three larger gene panels","volume":"144","author":"Endris","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/annonc\/mdz205","article-title":"Optimizing panel-based tumor mutational burden (TMB) measurement","volume":"30","author":"Budczies","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ijc.31878","article-title":"Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis","volume":"144","author":"Buchhalter","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Merino, D.M., McShane, L.M., Fabrizio, D., Funari, V., Chen, S.J., White, J.R., Wenz, P., Baden, J., Barrett, J.C., and Chaudhary, R. (2020). Establishing guidelines to harmonize tumor mutational burden (TMB): In silico assessment of variation in TMB quantification across diagnostic platforms: Phase I of the Friends of Cancer Research TMB Harmonization Project. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2019-000147"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2020.01.019","article-title":"Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement","volume":"142","author":"Budczies","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41698-021-00164-5","article-title":"Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups","volume":"5","author":"Asmann","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","article-title":"The cost of dichotomising continuous variables","volume":"332","author":"Altman","year":"2006","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","article-title":"Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S463","DOI":"10.1016\/j.annonc.2020.08.640","article-title":"526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours","volume":"31","author":"Rousseau","year":"2020","journal-title":"Ann. Oncol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/3\/432\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:28:20Z","timestamp":1760135300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/3\/432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,26]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["genes13030432"],"URL":"https:\/\/doi.org\/10.3390\/genes13030432","relation":{},"ISSN":["2073-4425"],"issn-type":[{"type":"electronic","value":"2073-4425"}],"subject":[],"published":{"date-parts":[[2022,2,26]]}}}